Sunlenca
Payments companies reported to CMS as associated with Sunlenca. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Sunlenca, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Sunlenca
These are the largest totals companies reported as associated with Sunlenca. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jihad Slim | Newark, NJ | Infectious Disease | $30,447.19 |
| Jeffrey Burack | Oakland, CA | Internal Medicine | $25,623.02 |
| James Sizemore | Chattanooga, TN | Infectious Disease | $15,979.67 |
| Todd Ellerin | Boston, MA | Infectious Disease | $14,534.44 |
| Jorge Rodriguez | Palm Springs, CA | Internal Medicine | $12,762.27 |
| Kjell Wiberg | Baltimore, MD | Infectious Disease | $12,709.97 |
| Madhuri Lad | Tulsa, OK | Internal Medicine | $12,111.97 |
| Frank Palella | Chicago, IL | Infectious Disease | $10,365.03 |
| Peter Gulick | Lansing, MI | Infectious Disease | $10,179.96 |
| Karam Mounzer | Philadelphia, PA | Infectious Disease | $9,776.86 |
Prescribed Sunlenca?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.